A recent change in the top management team at Walgreens Boots Alliance (WBA) has caught the attention of analysts who believe it could have significant implications for Amazon. Industry veteran Tim Wentworth has been appointed as the new CEO of Walgreens.
In its most recent quarterly report, Walgreens reported lower-than-expected earnings, which has further fueled interest in the company’s future direction. DA Davidson analysts, led by Tom Forte, who rate Amazon (AMZN) shares at Buy with a price target of $150, are closely monitoring Walgreens and CVS (CVS). These two companies could potentially impede Amazon’s efforts to gain market share in the healthcare sector.
Walgreens, in particular, has a strong presence in the pharmacy category, with physical locations across the globe. This positions them with a considerable competitive advantage, according to analysts. While Davidson remains optimistic about Amazon’s long-term potential to capitalize on the healthcare market opportunity, they believe there is a more than 10% chance that Amazon can achieve an incremental 100 basis points of revenue growth in 2026 through three key factors.
These factors include initiatives in pharmacy, collaboration between Amazon Web Services (AWS) and healthcare companies, and advancements in primary care. Davidson’s optimism is reflected in their Buy rating on Amazon shares.
In premarket trading, Amazon shares were up 0.5% to $132.44, while Walgreens stock rose 1.3% to $22.90.